As online ads abound for diabetes and obesity medications, endocrinologists should be prepared to talk to patients who may be attracted to GLP-1 drug lookalikes and supplements from questionable sources. GLP-1 agonists are a cultural phenomenon. Celebrities and social media influencers hyping the drugs’ weight-loss success has led to demand outstripping supply, resulting in shortages...
Vitamin D supplements may lower blood pressure in older people with obesity and taking more than the Institutes of Medicine’s (IOM) recommended daily dose does not provide additional health benefits, according to new research published in the Journal of the Endocrine Society. The IOM recommends 600 International Units (IU) per day. Vitamin D deficiency is common...
In the U.S., November is designated as American Diabetes Month. The World Health Organization sets aside November 14th as Diabetes Day. And here in the U.K., we blocked out June 10 – 16, 2024, as Diabetes Week. Globally, many other countries have similar diabetes mellitus recognition events in their calendars. Regardless of the dates on...
The Endocrine Society’s 2025 Fred Conrad Koch Lifetime Achievement Award recipient, Daniel Drucker, MD, first discovered his passion for science in high school when he learned “this is how stuff works.” He’s still learning to this day, and he tells Endocrine News about his ongoing scientific quests, the mentors who made a difference along the...
Congress Returns to Washington for “Lame Duck” Session and to Complete Work for 2024 Following the November elections, Congress will return to Washington, D.C., to complete work on federal funding and a package of several pieces of health legislation including many priorities of the Endocrine Society. Federal funding for the government expires December 20, 2024,...
Endocrine Society to host virtual Science Writers Conference Nov. 14 Surging demand for a new generation of highly effective anti-obesity medications is creating interest in compounded versions of these medications. Endocrine Society experts will discuss the importance of prescribing FDA-approved medications to treat obesity during the Society’s Virtual Science Writers Conference on November 14. What:...
On the heels of receiving nearly $10 million from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Rohit N. Kulkarni, MD, PhD, discusses how his team will use this grant to pursue new approaches to studying type 2 diabetes and obesity by exploring gene expression and regulatory activity in multiple metabolic cells. ...
Innovations on the forefront of glucose monitoring and insulin delivery are revolutionizing the state of diabetes care. Staying abreast of the latest advancements in diabetes technology is critical for improving patient care. The field of diabetes management continues to rapidly evolve with products designed to optimize glucose monitoring, insulin delivery, and patient convenience. Next-generation continuous...